<DOC>
	<DOCNO>NCT02379494</DOCNO>
	<brief_summary>To evaluate feasibility screen preeclampsia fetal growth restriction 11-13+6 week ' gestation utilize combination uterine artery doppler , maternal blood pressure , maternal characteristic , placental volume , maternal serum factor , include PAPPA-A , PLGF , AFP free Beta HCG . This non interventional study .</brief_summary>
	<brief_title>First Trimester Prediction Preeclampsia Fetal Growth Restriction</brief_title>
	<detailed_description>Preeclampsia ( PE ) condition affect approximately 2 % pregnancy major cause maternal perinatal morbidity/mortality ( 2 ) . The suspected underlying mechanism PE think impaired trophoblastic invasion maternal spiral artery lead impaired placental perfusion , placental ischemia subsequent development endothelial dysfunction ( 3 ) . There evidence PE , commonly associate fetal growth restriction , predict effectively 11-13 week gestational age combine screen algorithm combine uterine artery pulsatility index ( PI ) , maternal mean arterial pressure ( MAP ) maternal serum concentration placental product include limited plasma protein A ( PAPP-A ) , placental growth factor ( PLGF ) ( 4-6 ) . Aim Study/Hypothesis : The aim study develop algorithm base combination maternal factor , uterine artery pulsatility index , mean arterial pressure , placental volume serum biomarkers estimate patient specific risk development Preeclampsia US population .</detailed_description>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Fetal Growth Retardation</mesh_term>
	<criteria>All patient first trim visit Fetal anomalies Pregnancies end termination , miscarriage fetal death prior 22 week case pregnancy follow .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>